Evidence map›Paper›PMID 32613148›Full record

ReviewJACC. Basic to translational science2020

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.

Gary D Lopaschuk, Subodh Verma

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JACC. Basic to translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 513 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
513citing papers in PubMed, 14 pooled it
61.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07482943 phase4recruitingstarted 2026, after this paper: background citation

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

Ran2026Enrolled30Registered outcomes13Posted comparisons0ConditionsCardiovascular Diseases, Dapagliflozin, Fontan, Heart FailureArmsDapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
PMID 30340887PMID 33736819PMID 32098807PMID 31535829PMID 30895697PMID 29663436PMID 29495980PMID 29472024PMID 27257850PMID 22157969PMID 19915891PMID 17543747other papers from this trial
Open the trial in the graph
NCT04780438 early_phase1unknown statusnot on this mapstarted 2021, after this paper: background citation

Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

TypeinterventionalSponsorG.Gennimatas General HospitalRan2021 to 2023Enrolled350ConditionsAtrial Fibrillation Recurrent, Pulmonary Venous Isolation, Catheter Ablation, Sodium-glucose Co-transporter 2 InhibitorsArmsDapagliflozin, Placebo
3 · Its place in the literature

Who cites it

513 citing papers in PubMed, 14 syntheses or guidelines pooled it, 826 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

453 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Gary D LopaschukCardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
Subodh VermaDivision of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
University of Alberta · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of cardiovascular death and heart failure hospitalization in people with and without diabetes, and those with and without prevalent heart failure. The actual mechanism(s) responsible for these beneficial effects are not completely clear. Several potential theses have been proposed to explain the cardioprotective effects of SGLT2 inhibition, which include diuresis/natriuresis, blood pressure reduction, erythropoiesis, improved cardiac energy metabolism, inflammation reduction, inhibition of the sympathetic nervous system, prevention of adverse cardiac remodeling, prevention of ischemia/reperfusion injury, inhibition of the Na

Indexed as

EPO, erythropoietinerythropoetininflammationketonesLV, left ventricularNLRP3, nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing 3renal functionROS, reactive oxygen speciesSGLT, sodium glucose co-transporterSNS, sympathetic nervous systemsympathetic nervous systemT2DM, type 2 diabetes mellitus

Identifiers

PMID32613148
PMCPMC7315190
OpenAlexW3036816724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.